喘息の成人患者におけるルンセキミグ（SAR443765）の長期安全性および有効性評価。

基本情報

NCT ID

NCT06609239

ステータス

募集中

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

900

治験依頼者名

Sanofi

概要

This is a phase 2, open-label extension study to evaluate the long-term safety and efficacy of lunsekimig in adult participants with asthma who have previously completed the parent studies. After completion of the parent study, eligible participants will be offered the opportunity to participate in the long-term extension (LTE) study with lunsekimig. The study duration will be up to 100 weeks with a treatment duration being up to 96 weeks.

対象疾患

介入

依頼者（Sponsor）